Timing and optimized acquisition parameters for the whole-body imaging of 177Lu-EDTMP toward performing bone pain palliation treatment

Congjin Liu, James R Brasic, Xingdang Liu, Hongyu Li, Xueqin Xiang, Zhifu Luo, Yuankai Wang, Dayu Kuai, Guangming Zhang, John J. Zaknun

Research output: Contribution to journalArticle

Abstract

OBJECTIVES: Lutetium-177-labeled ethylenediamine-N,N,N′,N′- tetrakis (methylene phosphonic acid) ( 177Lu-EDTMP), a beta-emitting bone-seeking therapeutic radiopharmaceutical being assessed as an agent for palliation of bone pain, can emit suitable gamma-photons for scintigraphy. This investigation sought to characterize its optimal conditions for whole-body gamma camera imaging in patients. MATERIALS AND METHODS: Eleven patients with bone metastases underwent whole-body bone scanning using both 99mTc- methyl-diphosphonate ( 99mTc-MDP) and 177Lu-EDTMP (29.4±12.5 MBq/kg BW) utilizing a dual-head camera. For lutetium-177 imaging, two types of collimators, low-energy high-resolution (LEHR) and medium-energy general-purpose (MEGP), and two different peak energies of 113 and 208 keV were used. RESULTS: The femur-to-muscle uptake ratio (F/M) of 99mTC-MDP was 2.69±1.06. For 177Lu-EDTMP, the significantly highest F/Ms were found at 24 h (12.59±5.73) and 48 h (12.54±5.23) by applying MEGP collimators and collecting the 208 keV photons. In all the combinations of collimator and peak energy, the F/Ms at 24 and 48 h are significantly higher than those at 1 h, except the combination of LEHR collimator and 208 keV peak energy. Lesin-to-normal bone uptake ratios of the 99mTc-MDP bone scan and images at the 24 and the 48-h phases of 177Lu-EDTMP were analyzed. MEGP and 208 keV had significantly higher values in lesion-to-normal bone uptake ratios. The combination of LEHR and 208 keV provided the poorest images. CONCLUSION: 177Lu-EDTMP can provide fine whole-body images with the best results when applying medium-energy collimation and collecting the 208 keV energy photons and alternatively by collecting both 208 and 113 keV photons for higher count statistics. The most appropriate time point for imaging is around 24 h after injection.

Original languageEnglish (US)
Pages (from-to)90-96
Number of pages7
JournalNuclear Medicine Communications
Volume33
Issue number1
DOIs
StatePublished - Jan 2012

Fingerprint

Whole Body Imaging
Bone and Bones
Pain
Photons
Lutetium
ethylenediamine
Diphosphonates
Radionuclide Imaging
Therapeutics
Technetium Tc 99m Medronate
Radiopharmaceuticals
Body Image
Femur
Head
Neoplasm Metastasis
Muscles
Injections

Keywords

  • bone seeking radiopharmaceuticals
  • camera acquisition settings
  • lutetium-177-EDTMP
  • radionuclide therapy
  • whole-body imaging

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging

Cite this

Timing and optimized acquisition parameters for the whole-body imaging of 177Lu-EDTMP toward performing bone pain palliation treatment. / Liu, Congjin; Brasic, James R; Liu, Xingdang; Li, Hongyu; Xiang, Xueqin; Luo, Zhifu; Wang, Yuankai; Kuai, Dayu; Zhang, Guangming; Zaknun, John J.

In: Nuclear Medicine Communications, Vol. 33, No. 1, 01.2012, p. 90-96.

Research output: Contribution to journalArticle

Liu, Congjin ; Brasic, James R ; Liu, Xingdang ; Li, Hongyu ; Xiang, Xueqin ; Luo, Zhifu ; Wang, Yuankai ; Kuai, Dayu ; Zhang, Guangming ; Zaknun, John J. / Timing and optimized acquisition parameters for the whole-body imaging of 177Lu-EDTMP toward performing bone pain palliation treatment. In: Nuclear Medicine Communications. 2012 ; Vol. 33, No. 1. pp. 90-96.
@article{6f422e40d9bd4b9faa3466e843831ecf,
title = "Timing and optimized acquisition parameters for the whole-body imaging of 177Lu-EDTMP toward performing bone pain palliation treatment",
abstract = "OBJECTIVES: Lutetium-177-labeled ethylenediamine-N,N,N′,N′- tetrakis (methylene phosphonic acid) ( 177Lu-EDTMP), a beta-emitting bone-seeking therapeutic radiopharmaceutical being assessed as an agent for palliation of bone pain, can emit suitable gamma-photons for scintigraphy. This investigation sought to characterize its optimal conditions for whole-body gamma camera imaging in patients. MATERIALS AND METHODS: Eleven patients with bone metastases underwent whole-body bone scanning using both 99mTc- methyl-diphosphonate ( 99mTc-MDP) and 177Lu-EDTMP (29.4±12.5 MBq/kg BW) utilizing a dual-head camera. For lutetium-177 imaging, two types of collimators, low-energy high-resolution (LEHR) and medium-energy general-purpose (MEGP), and two different peak energies of 113 and 208 keV were used. RESULTS: The femur-to-muscle uptake ratio (F/M) of 99mTC-MDP was 2.69±1.06. For 177Lu-EDTMP, the significantly highest F/Ms were found at 24 h (12.59±5.73) and 48 h (12.54±5.23) by applying MEGP collimators and collecting the 208 keV photons. In all the combinations of collimator and peak energy, the F/Ms at 24 and 48 h are significantly higher than those at 1 h, except the combination of LEHR collimator and 208 keV peak energy. Lesin-to-normal bone uptake ratios of the 99mTc-MDP bone scan and images at the 24 and the 48-h phases of 177Lu-EDTMP were analyzed. MEGP and 208 keV had significantly higher values in lesion-to-normal bone uptake ratios. The combination of LEHR and 208 keV provided the poorest images. CONCLUSION: 177Lu-EDTMP can provide fine whole-body images with the best results when applying medium-energy collimation and collecting the 208 keV energy photons and alternatively by collecting both 208 and 113 keV photons for higher count statistics. The most appropriate time point for imaging is around 24 h after injection.",
keywords = "bone seeking radiopharmaceuticals, camera acquisition settings, lutetium-177-EDTMP, radionuclide therapy, whole-body imaging",
author = "Congjin Liu and Brasic, {James R} and Xingdang Liu and Hongyu Li and Xueqin Xiang and Zhifu Luo and Yuankai Wang and Dayu Kuai and Guangming Zhang and Zaknun, {John J.}",
year = "2012",
month = "1",
doi = "10.1097/MNM.0b013e32834d3c13",
language = "English (US)",
volume = "33",
pages = "90--96",
journal = "Nuclear Medicine Communications",
issn = "0143-3636",
publisher = "Lippincott Williams and Wilkins",
number = "1",

}

TY - JOUR

T1 - Timing and optimized acquisition parameters for the whole-body imaging of 177Lu-EDTMP toward performing bone pain palliation treatment

AU - Liu, Congjin

AU - Brasic, James R

AU - Liu, Xingdang

AU - Li, Hongyu

AU - Xiang, Xueqin

AU - Luo, Zhifu

AU - Wang, Yuankai

AU - Kuai, Dayu

AU - Zhang, Guangming

AU - Zaknun, John J.

PY - 2012/1

Y1 - 2012/1

N2 - OBJECTIVES: Lutetium-177-labeled ethylenediamine-N,N,N′,N′- tetrakis (methylene phosphonic acid) ( 177Lu-EDTMP), a beta-emitting bone-seeking therapeutic radiopharmaceutical being assessed as an agent for palliation of bone pain, can emit suitable gamma-photons for scintigraphy. This investigation sought to characterize its optimal conditions for whole-body gamma camera imaging in patients. MATERIALS AND METHODS: Eleven patients with bone metastases underwent whole-body bone scanning using both 99mTc- methyl-diphosphonate ( 99mTc-MDP) and 177Lu-EDTMP (29.4±12.5 MBq/kg BW) utilizing a dual-head camera. For lutetium-177 imaging, two types of collimators, low-energy high-resolution (LEHR) and medium-energy general-purpose (MEGP), and two different peak energies of 113 and 208 keV were used. RESULTS: The femur-to-muscle uptake ratio (F/M) of 99mTC-MDP was 2.69±1.06. For 177Lu-EDTMP, the significantly highest F/Ms were found at 24 h (12.59±5.73) and 48 h (12.54±5.23) by applying MEGP collimators and collecting the 208 keV photons. In all the combinations of collimator and peak energy, the F/Ms at 24 and 48 h are significantly higher than those at 1 h, except the combination of LEHR collimator and 208 keV peak energy. Lesin-to-normal bone uptake ratios of the 99mTc-MDP bone scan and images at the 24 and the 48-h phases of 177Lu-EDTMP were analyzed. MEGP and 208 keV had significantly higher values in lesion-to-normal bone uptake ratios. The combination of LEHR and 208 keV provided the poorest images. CONCLUSION: 177Lu-EDTMP can provide fine whole-body images with the best results when applying medium-energy collimation and collecting the 208 keV energy photons and alternatively by collecting both 208 and 113 keV photons for higher count statistics. The most appropriate time point for imaging is around 24 h after injection.

AB - OBJECTIVES: Lutetium-177-labeled ethylenediamine-N,N,N′,N′- tetrakis (methylene phosphonic acid) ( 177Lu-EDTMP), a beta-emitting bone-seeking therapeutic radiopharmaceutical being assessed as an agent for palliation of bone pain, can emit suitable gamma-photons for scintigraphy. This investigation sought to characterize its optimal conditions for whole-body gamma camera imaging in patients. MATERIALS AND METHODS: Eleven patients with bone metastases underwent whole-body bone scanning using both 99mTc- methyl-diphosphonate ( 99mTc-MDP) and 177Lu-EDTMP (29.4±12.5 MBq/kg BW) utilizing a dual-head camera. For lutetium-177 imaging, two types of collimators, low-energy high-resolution (LEHR) and medium-energy general-purpose (MEGP), and two different peak energies of 113 and 208 keV were used. RESULTS: The femur-to-muscle uptake ratio (F/M) of 99mTC-MDP was 2.69±1.06. For 177Lu-EDTMP, the significantly highest F/Ms were found at 24 h (12.59±5.73) and 48 h (12.54±5.23) by applying MEGP collimators and collecting the 208 keV photons. In all the combinations of collimator and peak energy, the F/Ms at 24 and 48 h are significantly higher than those at 1 h, except the combination of LEHR collimator and 208 keV peak energy. Lesin-to-normal bone uptake ratios of the 99mTc-MDP bone scan and images at the 24 and the 48-h phases of 177Lu-EDTMP were analyzed. MEGP and 208 keV had significantly higher values in lesion-to-normal bone uptake ratios. The combination of LEHR and 208 keV provided the poorest images. CONCLUSION: 177Lu-EDTMP can provide fine whole-body images with the best results when applying medium-energy collimation and collecting the 208 keV energy photons and alternatively by collecting both 208 and 113 keV photons for higher count statistics. The most appropriate time point for imaging is around 24 h after injection.

KW - bone seeking radiopharmaceuticals

KW - camera acquisition settings

KW - lutetium-177-EDTMP

KW - radionuclide therapy

KW - whole-body imaging

UR - http://www.scopus.com/inward/record.url?scp=82555205254&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=82555205254&partnerID=8YFLogxK

U2 - 10.1097/MNM.0b013e32834d3c13

DO - 10.1097/MNM.0b013e32834d3c13

M3 - Article

C2 - 22001721

AN - SCOPUS:82555205254

VL - 33

SP - 90

EP - 96

JO - Nuclear Medicine Communications

JF - Nuclear Medicine Communications

SN - 0143-3636

IS - 1

ER -